What are targeting therapies for breast cancer?
Best insight from top research papers
Targeted therapies for breast cancer include monoclonal antibodies such as trastuzumab, pertuzumab, and margetuximab, which target the HER2 receptor . Other targeted therapies include antibody-drug conjugates like trastuzumab-emtansine (T-DM1) and trastuzumab-deruxtecan (T-DXd), as well as tyrosine kinase inhibitors such as lapatinib and tucatinib . Additionally, there are emerging therapies like immunotherapy and targeted therapy against critical checkpoints and pathways in cell growth . Ablative techniques such as cryoablation, radiofrequency ablation, microwave ablation, high-intensity focused ultrasound, and laser ablation are also being used as minimally invasive treatments for breast cancer . Nanomedicine and ultrasound-responsive biocompatible carriers are being explored to enhance drug delivery to breast cancer cells . These targeted therapies aim to improve treatment outcomes and overcome resistance to therapy in breast cancer patients.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| The paper discusses targeted therapies for breast cancer, including HER2-targeted therapy, immunotherapy, and targeted therapy against critical checkpoints and pathways in cell growth. | |
1 Citations | The paper discusses several targeting therapies for breast cancer, including targeting major oncoproteins, inhibiting pathways that drive cell proliferation, using molecular classifiers for therapy selection, and exploiting unique vulnerabilities induced by molecular alterations. |
| The paper does not provide specific information about targeting therapies for breast cancer. | |
1 Citations | The provided paper does not specifically discuss targeting therapies for breast cancer. It focuses on percutaneous minimally invasive techniques (PMIT) such as cryoablation, radiofrequency ablation, microwave ablation, high-intensity focused ultrasound, and laser ablation as alternative treatments for early-stage breast cancer. |
| The paper discusses various targeted therapies for HER2-positive breast cancer, including monoclonal antibodies (trastuzumab, pertuzumab, margetuximab), antibody-drug conjugates (T-DM1, T-DXd), and tyrosine kinase inhibitors (lapatinib, tucatinib). |
Related Questions
What are the current targeted therapies in development for metastatic breast cancer?4 answersCurrent targeted therapies in development for metastatic breast cancer include molecules like cyclin D-dependent kinases CDK4 and CDK6, the PI3K/AKT/mTOR pathway, the insulin/IGF1R pathway, the EGFR/HER family, the JAK/STAT pathway, poly(ADP-ribose) polymerases (PARP), TROP-2, Src kinases, histone modification enzymes, activated growth factor receptors, androgen receptors, breast cancer stem cells, matrix metalloproteinases, and immune checkpoint proteins. Additionally, therapies targeting HER2-positive breast cancer involve monoclonal antibodies like trastuzumab, pertuzumab, and margetuximab, antibody-drug conjugates such as trastuzumab-emtansine (T-DM1) and trastuzumab-deruxtecan (T-DXd), and tyrosine kinase inhibitors like lapatinib and tucatinib. These targeted therapies aim to overcome drug resistance and achieve better clinical outcomes by simultaneously targeting multiple oncogenic signaling pathways, providing promising prospects for improving the quality of life and survival rates of patients with metastatic breast cancer.
What are the potential therapeutic targets for modulating Nf Kb protein concentration in breast cancer patients?4 answersThe potential therapeutic targets for modulating Nf Kb protein concentration in breast cancer patients include the proteins c-Rel, RelA(p65), RelB, NF-κB1(p50), and NF-κB2(p52). Inhibiting the NF-κB pathway using natural and synthetic compounds has shown promise in blocking or targeting NF-κB signaling. Additionally, the inhibitors bisindolylmaleimide I (BIS), MG132, curcumin, and dehydroxymethylepoxyquinomicin have been found to effectively inhibit the constitutive activation of NF-κB in triple-negative breast cancer (TNBC) cell lines. The NGF/NF-κB pathway has also been identified as a potential therapeutic target in breast cancer, with inhibitors of the NGF receptors p75NTR and p140TrkA, as well as the NF-κB inhibitor BAY11-7085, showing pro-apoptotic and anti-proliferation activities. Furthermore, nuclear NF-kB expression has been associated with high histological grade, ER negativity, and high Ki67 index in breast cancer patients, and targeting NF-kB has shown a higher pathological complete response rate in neoadjuvant systemic treatment.
What novel drug targets are of the highest prioirity in regards to breast cancer?4 answersNovel drug targets of high priority in breast cancer include cyclin D-dependent kinases CDK4 and CDK6, the PI3K/AKT/mTOR pathway, the insulin/IGF1R pathway, the EGFR/HER family, the JAK/STAT pathway, poly(ADP-ribose) polymerases (PARP), TROP-2, Src kinases, histone modification enzymes, activated growth factor receptors, androgen receptors, breast cancer stem cells, matrix metalloproteinases, and immune checkpoint proteins. Other emerging targets for triple-negative breast cancer (TNBC) treatment include cancer cell membrane molecules, hyperactive intracellular signaling pathways, and the tumor microenvironment (TME). In hormone receptor positive (HR+) breast cancer, the development of new ER pathway targeting agents is essential, such as oral selective ER degraders (SERDs), selective ER modulators (SERMs), ER proteolysis targeting chimera (PROTACs), selective ER covalent antagonists (SERCAs), complete ER antagonists (CERANs), and selective human ER partial agonists (ShERPAs). Immunotherapy also plays a significant role, with chimeric antigen receptor-T cells (CAR-T) and bispecific antibodies (BsAb) being promising approaches, especially for TNBC. Overall, these targets offer potential for the development of novel therapies and improving treatment efficacy in breast cancer.
What are targeting ligands for targeted cancer therapy?5 answersTargeting ligands for targeted cancer therapy include AB toxins, phytoestrogens, small molecules, and aptamers. AB toxins are highly poisonous molecules that have a nanomolar affinity for their target cell receptors, making them promising tools for developing new methods for targeting anticancer therapies. Phytoestrogens, specifically tanshinone IIA, have shown good biosafety characteristics and affinity for estrogen receptors, making them suitable ligands for nanodelivery systems in breast tumors. Small molecules, including chemotherapeutics, have a higher affinity for cancer receptors and can assist in drug cellular uptake through endocytosis. Aptamers, such as those targeting tumor markers and glycoproteins, have high target affinity and specificity, making them attractive ligands for targeted drug delivery in cancer therapy.
What makes a good therapeutic target for cancer?5 answersA good therapeutic target for cancer should have several characteristics. Firstly, it should be involved in key biological functions and pathologies of cancer, such as tumor growth, progression, and metastasis. Secondly, it should be tightly regulated and dysregulation of its activity should be linked to the promotion of cancer hallmarks, such as proliferation, survival, and chemotherapeutic resistance. Thirdly, it should play a critical role in the tumor microenvironment, which consists of non-cancerous cells and components that interact with tumor cells. Lastly, it should have the potential to be targeted for therapeutic intervention, either by direct inhibition or by targeting downstream proteins. By targeting such molecules, it may be possible to disrupt tumor growth and progression, enhance therapeutic efficacy, and improve patient outcomes.
How Cancer targeting drug works?3 answersTargeted drug delivery in cancer works by using specific ligands or moieties to selectively deliver drugs to tumor cells while minimizing damage to normal cells. Various functional ligands, such as transferrin, folic acid, polypeptide, and hyaluronic acid, have been explored to develop tumor-selective drug delivery systems. Nanoplatforms and nanocarriers are used to improve drug pharmacokinetics and increase drug concentration at the cancer site. Targeted drug therapy can inhibit proliferation, induce apoptosis, suppress metastases, regulate immune function, and reverse multidrug resistance. It can be achieved through monoclonal antibodies or small molecule inhibitors that target specific molecular pathways or targets in cancer cells. The development of technology, such as proteomics and genomics, has further advanced targeted drug therapy. Additionally, targeted therapy can interact with the immune system, creating a connection with immunotherapy. Through continuous research and development, targeted cancer drugs have the potential to become an essential platform for accurate cancer treatment.